English   español  
Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/32440
logo share SHARE logo core CORE   Add this article to your Mendeley library MendeleyBASE

Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar a otros formatos:


Uric acid administration in patients with acute stroke: a novel approach to neuroprotection

AuthorsAmaro, Sergio; Planas, Anna M. ; Chamorro, Ángel
KeywordsCerebrovascular disorder
Clinical trials
Oxidative stress
Issue DateFeb-2008
PublisherFuture Drugs
CitationExpert Review of Neurotherapeutics 8(2): 259-270 (2008)
AbstractUric acid (UA) is the end product of purine catabolism in humans and is a powerful antioxidant whose generation is increased under ischemic conditions. However, both clinical and experimental studies reveal a gradual exhaustion of the antioxidant capacity after transient cerebral ischemia, and the magnitude of this consumption seems to be correlated with the extent of brain tissue injury, growth of the infarction, severity of neurological impairment in the acute phase, and long-term functional outcome. Growing evidence supports the neuroprotective effect of UA administration after brain ischemia. In experimental conditions, the administration of UA is neuroprotective both in mechanical models of brain ischemia (transient or permanent intraluminal occlusion of the middle cerebral artery) and in thromboembolic models of autologous clot injection. The administration of UA is feasible and safe in healthy volunteers. In acute stroke patients treated with recombinant tissue plasminogen activator (rt-PA), co-administration of UA has proven to reduce lipid peroxidation and to prevent the fall in UA blood levels that occur very early after stroke onset. Currently, a multicentric Phase III clinical trial is testing whether the administration of UA increases the clinical benefits of rt-PA, which represents the only approved therapy in patients with acute ischemic stroke. This review summarizes the available information justifying such a novel therapeutic approach in this devastating clinical condition.
Publisher version (URL)http://dx.doi.org/10.1586/14737175.8.2.259
Appears in Collections:(IIBB) Artículos
Files in This Item:
File Description SizeFormat 
Uric acid administration.pdf544,04 kBAdobe PDFThumbnail
Show full item record
Review this work

Related articles:

WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.